Emilia D’eLia

Emilia D’eLia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emilia D’eLia has a total of 300 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Anemia and Iron Deficiency Across Renal Function in Hospitalized Heart Failure

    by Luca Fazzini, Cinzia Giaccherini, Marco Spagnolin, Emilia D’ELia, Erika Chiesa, Alberto Zucchi, Antonello Gavazzi, Mauro Gori, Michele Senni

  • Open Access

    Sex-based differences in chronic heart failure: a systematic review and meta-analysis of randomized controlled trials

    by Luca Fazzini, Luca Pascalis, Cristina Madaudo, Giordano Maria Pugliesi, Paolo Manca, Vincenzo Nuzzi, Gregorio Tersalvi, Emilia D’ELia, Christian Cadeddu Dessalvi, Roberta Montisci, et al.

    Background: Sex-based disparities in patient enrolment and treatment effects in heart failure (HF) randomized controlled trials (RCTs) have been reported. We aim to systematically analyse sex-based enrolment and treatment effect differences in HF RCTs over time. Methods: RCTs enrolling patients with chronic HF were systematically searched on PubMed-MEDLINE. Eligible trials included pharmacological or device-based interventions with a hard primary endpoint (mortality and hospitalization) and reporting enrolment of women. Sex-specific treatment effects (hazard ratio [HR] or risk ratio [RR]) were extracted. Meta-analyses were performed using random-effects models, and pre-specified subgroup analyses were performed. Results: A total of 56 RCTs (39 drug, 17 device) were included. The pooled proportion of women enrolment was 27.0% (95% confidence interval [CI]: 22.0%–32.4%) in drug trials and 25.3% (95% CI: 21.0%–29.9%) in device trials. Women were more underrepresented in HF with reduced ejection fraction (HFrEF) than in HF with preserved EF (HFpEF) trials (21.0% vs 49.6%, P < .001). Among drug trials reporting sex-specific effects, the pooled sex interaction for RCTs reporting HR was 0.94 (95%CI 0.89–1.01) and RR was 0.81 (95% CI 0.68–0.96), suggesting potentially greater benefit for women. No interaction was observed between HFrEF and HFpEF trials (HR: P = 0.44; RR: P = .95). The pooled interaction estimate on event counts was 0.90 (95%CI 0.84–0.96). For devices, the pooled sex interaction for RCTs reporting HR was 1.05 (95% CI 0.90–1.22) and RR was 0.68 (95% CI 0.50–0.93). Conclusion: Women remain underrepresented in HF RCTs. Sex-stratified analyses suggest a potentially greater relative benefit of drug intervention in women, which might inform future RCTs. Further studies are required to investigate the mechanisms of these differences.


  • Open Access

    Variation in initial and sequential medical therapy for heart failure with reduced ejection fraction: an international case-based survey

    by Hesam Amin, Hans-Peter Brunner-La Rocca, Aldostefano Porcari, Emiliano Fiori, Emilia D'ELia, Jurren van Opstal, G.C.M. Linssen, Otilia Tica, Andreas Gevaert, Takeru Nabeta, et al.

    BackgroundGuideline-directed medical therapy (GDMT) improves outcomes in heart failure with reduced ejection fraction (HFrEF), but guidelines do not specify which therapy should be initiated first. Although expert consensus documents propose phenotype-based initiation strategies, the extent of shared prioritisation patterns among health care professionals (HCPs) remains unknown.MethodsTo investigate variation in the initiation of medical therapy in HFrEF, we conducted a web-based survey (January-November 2025) in which European HCPs evaluated 12 treatment-naïve cases based on phenotypic profiles and selected first and second pharmacological treatment classes per case. First-step treatment choices were described overall and across medical specialities. Coverage of two GDMT pillars across both sequential choices was assessed by patient phenotype and HCP group.Results121 European HCPs evaluated 12 phenotypically diverse cases. A median of seven distinct medication classes was selected per case; sodium-glucose cotransporter-2 inhibitors were the most frequently chosen first-step therapy (7/12 cases, 58%), with convergence exceeding 60% in three low-blood-pressure cases. HF cardiologists showed greater within-group alignment than general cardiologists (majority agreement in 58% vs. 8% of cases; p=0.027). Two-pillar GDMT coverage was high in uncomplicated cases (97–98%) but fell substantially in haemodynamically constrained phenotypes (67–82%); HF nurses achieved the lowest median coverage (63%), versus other groups (p<0.001).ConclusionInitial pharmacological treatment choices for HFrEF varied considerably, without consensus on preferred first-step therapies; however, convergence was observed in low-blood-pressure phenotypes. Two-pillar GDMT coverage, across two consecutive treatment choices, was high in uncomplicated cases but reduced in haemodynamically constrained phenotypes and among less specialised HCP groups.

  • Open Access

    Obstructive Intramural Coronary Amyloidosis

    by Luca Fazzini, Emilia D'ELia, Edoardo Sciatti, Giulia Togni, Michele Senni, Eloisa Arbustini

  • Open Access

    Strategies for preventing and reversing atrial cardiomyopathy: current evidence, therapeutic targets, and future directions. A European Journal of Heart Failure expert consensus statement

    by Rosita Zakeri, Massimiliano Camilli, Emilia D’ELia, Jean Sebastien Hulot, Massimo Iacoviello, Nicolò Sisti, Otilia Tica, Mariya Tokmakova, Jef Van Den Eynde, Jerremy Weerts, et al.

    Atrial cardiomyopathy (AtCM) encompasses all forms of electrical atrial dysfunction in combination with mechanical atrial dysfunction, atrial enlargement, and/or excessive atrial fibrosis. A growing body of evidence suggests that AtCM not only represents a consequence of ventricular and valvular heart disease but also, critically, serves as the substrate driving atrial fibrillation (AF) and independently contributes to thromboembolic risk and heart failure (HF). Recent advances in cardiac imaging, electrocardiography, and electroanatomic mapping have enabled characterization of AtCM and quantification of its severity, defining a continuum from atrial health to overt atrial failure. This framework creates an opportunity for targeted interventions that may reverse AtCM and prevent progression to clinical disease. This scientific statement summarizes contemporary evidence regarding the natural history, determinants, and therapeutic modification of AtCM. We describe how targeted management of relevant lifestyle factors and comorbidities may prevent or attenuate AtCM progression and report the response of AtCM to pharmacological and structural interventions for HF and valve disease. Recognition of the bidirectional relationship between AtCM and AF has provided important insights into arrhythmia-mediated remodelling and generated the strongest evidence to date for reverse atrial remodelling following successful rhythm-control strategies. We also review emerging atrial-directed therapies targeting fibrosis, inflammation, metabolic dysfunction, and infiltrative disease. While AtCM appears to be, at least in part, a modifiable disease process, current evidence remains largely observational or mechanistic. We therefore highlight key evidence gaps and future research priorities to identify potentially reversible disease, develop targeted therapies, and translate state-of-the-art atrial phenotyping into improved patient outcomes.

  • Impact of D-type personality and depressive symptoms on functional status and quality of life in worsening heart failure

    by Georgiana Maria Costandache, Luca Fazzini, Gionata Guastamiglio, Romina Adobati, Cinzia Begnis, Michele Senni, Emilia D’ELia

  • Understanding Geographic Variations in Heart Failure Clinical Trials

    by Luca Fazzini, Giada Colombo, Gregorio Tersalvi, Jolie Bruno, Riccardo M. Inciardi, Emilia D’ELia

  • Open Access

    Medical treatments at 6 months in hospitalized and ambulatory HFrEF patients in the BRING-UP 3 Heart Failure study

    by Fabrizio Oliva, Francesco Orso, Furio Colivicchi, Manlio Gianni Cipriani, Andrea Di Lenarda, Mauro Gori, Marco Gorini, Massimo Iacoviello, Donata Lucci, Marco Marini, et al.

    Introduction: The BRING-UP 3 Heart Failure (HF) study was designed to evaluate the real-world implementation of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF), given the limited evidence on the uptake of the contemporary four-pillar treatment strategy. Methods: BRING-UP 3 HF study is an observational, prospective, nationwide investigation encompassing 179 sites. This analysis includes HFrEF patients enrolled in the ambulatory and hospitalized cohorts with complete pharmacological data at 6-month follow-up. The objective was to describe the use of the four GDMT pillars after 6 months. Results: Among 3201 HFrEF patients enrolled, 142 (4.4%) had died by 6 months, and treatment data were available for 2950 patients. Mean age was 69 ± 11 years (26.6% > 75 years), 18.0% were female. Prescription rates of GDMT were high at baseline and remained stable over 6-months, with a shift from ACE-I/ARBs to ARNIs, and a modest increase in SGLT2i use. A significant reduction in diuretic prescription was also observed. Quadruple therapy was prescribed in 64.3% of patients at 6 months versus 63.9% at baseline/discharge (P = NS), while quadruple therapy including ARNI went from 52.9% to 55.9%, P < .0001. Dose up-titration of GDMT remained suboptimal, with most agents prescribed at <50% of target doses. Discontinuation rates at follow-up were very low. Conclusion: In this large nationwide cohort, guideline-directed therapies for HFrEF were widely implemented and maintained over 6 months with excellent treatment persistence. However, dose optimization remains a key unmet need in routine clinical practice.


  • Open Access

    Clinical and echocardiographic changes after intermittent levosimendan infusion in patients with advanced heart failure

    by Mauro Riccardi, Emilia D’eLia, Fabio Fazzari, Camilla Cirelli, Stefano Bisegna, Maria Giulia Bellicini, Matteo Pagnesi, Savina Nodari, Daniela Pini, Renato M Bragato, et al.

    Introduction: To evaluate the short-term clinical, structural, and functional cardiac changes following intermittent levosimendan infusion and their prognostic implications in patients with advanced heart failure (AdHF). Methods: In this prospective, multicentre, observational study, patients with AdHF treated with intermittent levosimendan infusion (12.5 mg at a rate of 0.1 μg/kg/min, without a bolus) were enrolled. Clinical, laboratory, and comprehensive echocardiographic assessments were performed at baseline, 48 h, and 30 days post-infusion. The primary endpoint was to evaluate the extent of clinical and cardiac structure and function changes during the first 30 days after levosimendan infusion. Secondary outcome of interest was the association of cardiac changes and a composite endpoint of decompensated HF, urgent HF rehospitalization, cardiogenic shock, cardiac arrest, and cardiovascular death at 6 months. Results: A total of 37 patients with AdHF were included (mean age 71.1 ± 9.0 years; 59.5% male). A non-significant trend reduction in mean arterial pressure values was observed over time (81.3 ± 9.5 mmHg vs 80.9 ± 7.7 mmHg after 48 h vs 79.1 ± 6.9 mmHg at 30 days, P-value for trend = .079). NT-proBNP levels significantly decreased at 48 h and rose again by 30 days [from 1802 (1127–4436) ng/l to 1060 (830–3864) ng/l at 48 h and 1661 (1015–4245) ng/l at 30 days, P-value for trend = .006]. The main left ventricular (LV) and right ventricular (RV) structure and function parameters improved at 48 h but returned to baseline or a slight improvement by 30 days (LV ejection fraction: 30.9 ± 11.3% vs 32.2 ± 11.2%, vs 30.9 ± 11.3%, P-value for trend = .001; LV global longitudinal strain: −8.0 ± 3.5% vs −9.2 ± 3.5% vs −8.0 ± 3.3%, P-value for trend < .001; tricuspid annular plane systolic excursion: 16.9 ± 3.1 mm vs 17.7 ± 3.4 vs 17.0 ± 3.5, P-value for trend .007; systolic pulmonary artery pressure: 48.7 ± 15.8 mmHg vs 41.6 ± 12.7 mmHg vs 46.1 ± 15.0, P-value for trend <.001). Overall, 17 (45.9%) patients experienced CV events. After accounting for confounders, ΔLV global longitudinal strain (GLS) after 48 h (adjusted odds ratio (OR) 0.26, 95% confidence interval (CI) 0.10–0.67, P = .006) and ΔRV free wall longitudinal strain (FWLS) (adjusted OR 0.75, 95% CI 0.57–0.99, P = .041) were significantly associated with a lower risk of events. Conclusions: In patients with AdHF, intermittent levosimendan infusion resulted in early improvements in NT-proBNP levels and biventricular function, which tended to wane by 30 days. Early enhancements in LVGLS and RVFWLS were independently associated with better clinical outcomes, suggesting their potential role as markers to guide patient selection and therapeutic response.

  • Open Access

    Sex-related disparities in elderly patients with heart failure with mildly reduced or preserved ejection fraction

    by Emilia D’eLia, Raul Limonta, Cinzia Giaccherini, Christian Basile, Edoardo Sciatti, Ottavio Zucchetti, Luca Di Odoardo, Salvatore D’iSa, Erika Chiesa, Mauro Gori, et al.

    Introduction: Heart failure with preserved or mildly reduced ejection fraction (HFmrEF/HFpEF) is a complex syndrome common in elderly patients with multiple comorbidities. Age and sex affect the clinical phenotypes and outcomes of this condition. This study aimed to identify age- and sex-specific factors influencing prognosis in elderly patients with HFmrEF/HFpEF to improve risk stratification and guide personalized treatment. Methods: This observational, ambispective study was conducted at Papa Giovanni XXIII Hospital, Bergamo, from June 2017 to August 2022, enrolling patients >65 years with HFmrEF/HFpEF [New York Heart Association (NYHA) Class II–IV] according to ESC guidelines. Data collected included demographics, medical history, echocardiograms, and lab tests. Follow-up lasted at least 1 year, with outcomes defined as a composite of all-cause death, urgent heart transplant, HF hospitalization, and emergency department referral for decompensated HF. Findings were validated using the Swedish HF registry with a similar cohort. Results: Among 2263 HF patients, 971 HFmrEF/HFpEF patients (56.8% males, mean age 79.2 years) were analysed. Males had a higher prevalence of cardiovascular risk factors (e.g. diabetes, obesity, coronary artery disease). The composite outcome occurred more frequently in males (20.6 vs 17.14 per 100 patient years; IRR = 1.20, P = .035). Multivariable analysis identified male sex (HR 1.40, 95% CI 1.13–1.73), age >80 years (HR 1.91, 95% CI 1.22–3.00), higher NYHA class, chronic kidney disease, and severe valvular heart disease as independent predictors of worse outcomes. Males had a 40% higher risk of the outcome compared with women (HR 1.40, 95% CI 1.13–1.73), while patients >80 years old had nearly double the risk compared with those aged 65–70 (HR 1.91, 95% CI 1.22–3.00). The validation analysis in the SwedeHF, adapting the same multiple Cox regression model on 20 950 selected patients, median age 79 years and 57.8% men, and observed between January 2017 and August 2022, showed similar independent risk factors for the composite outcome. Conclusion: This study highlights significant sex disparities in elderly HFmrEF/HFpEF patients, with higher age and male sex being an independent predictor for poor outcomes. These findings emphasize the need for personalized treatment strategies based on these demographic factors.